Dapagliflozin plus Saxagliptin Add-On vs. Glimepiride Add-On to Metformin in Patients with Poorly Controlled Type 2 Diabetes

Add-on therapy with a single oral antihyperglycemic agent is often insufficient to provide glycemic control in patients with type 2 diabetes (T2D) uncontrolled on metformin (MET) monotherapy. This randomized, parallel-group, double-blind, 52-week trial (NCT02419612) evaluated the efficacy and safety of dual add-on therapy with dapagliflozin (DAPA) 10 mg/d + saxagliptin (SAXA) 5 mg/d vs. single add-on of titrated glimepiride (GLIM) 1-6 mg/d in patients with T2D (A1C, 7.5-10.5%) receiving stable MET ≥1500 mg/d. The primary end point was change in A1C from baseline to week 52; secondary end points were changes in body weight and systolic blood pressure (SBP) and the proportions of patients achieving A1C